A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants.
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs MK 8189 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms MDCS
- Sponsors Merck Sharp & Dohme
- 23 Sep 2019 Planned number of patients changed from 56 to 64.
- 23 Sep 2019 Planned End Date changed from 15 Dec 2019 to 5 Jan 2020.
- 23 Sep 2019 Planned primary completion date changed from 15 Dec 2019 to 5 Jan 2020.